VMocion secures $3M for virtual motion technology
04 Jan 2024
Preview
Source: mobihealthnews
Photo: Caiaimage/Agnieszka Olek/Getty Images
VMocion, a technology company focused on allowing users to "feel" the motion they see in extended reality (XR) experiences, announced it secured $3 million in seed funding.
AZ Crown and Mayo Clinic participated in the round.
Eric Crown of Insight Enterprises will join the company's board of directors.
WHAT IT DOES
VMocion's 3V technologies provide users with a sense of physical motion while in extended reality, which includes virtual reality, augmented reality and mixed reality.
The company says its WAIV algorithmic technology eliminates motion sickness, which some users experience while in an extended reality setting, by sending electrical impulses to one's inner ear via wearable contact points placed on the skin.
The impulses stimulate the ear's vestibular system, awhich creates a sense of balance and spatial orientation in the human body to coordinate movement with balance.
VMocion says the technology gives users a virtually simulated sense of physical motion that matches what they see on screen.
The Arizona-based company will use the funds to advance its technology.
MARKET SNAPSHOT
Another company working to make extended reality feel more realistic is OVR Technology.
OVR offers ION, its wearable scent technology that utilizes a cartridge that attaches to a virtual reality headset. The cartridge gives off scents, allowing users to experience the smell of the virtual environment.
Tags: vMocion, extended reality, virtual reality, motion sickness
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.